Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekPharmaVoice ↗
The dueling modalities are each gaining traction in lung cancer. But will they ultimately become allies?…
The WeekBioPharma Dive ↗
The results support Takeda's long-held belief in zasocitinib's superiority and could help it gain a commercial…
The WeekFiercePharma ↗
Three short films created through an Eli Lilly-sponsored initiative are premiering at the Tribeca Festival, fu…
The WeekFierceBiotech ↗
When Charles River Laboratories CEO Birgit Girshick started her career as an executive assistant with the comp…
The WeekBriefing
The NIH is considering limiting the number of grants each principal investigator can hold, aiming to reduce co…
The WeekDrug Channels ↗
This week, we're rerunning some popular posts while we prepare for tomorrow's live video webinar: 340B in 2026…
The WeekDrug Channels ↗
This week, we're rerunning some popular posts while we prepare for tomorrow's live video webinar: 340B in 2026…
The WeekDrug Channels ↗
This week, we're rerunning some popular posts while we prepare for tomorrow's live video webinar: 340B in 2026…
The WeekSTAT News ↗
Long Covid hasn't disappeared. It's just gone underground, writes Steven Phillips.…
The WeekAJMC ↗
Special Report: The Oncology Care Model, 10 Years Later…
The WeekBioPharma Dive ↗
The startup is developing a medicine that works differently than available treatments for thyroid eye disease …
The WeekPharmaVoice ↗
The country's new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients,…
The WeekFiercePharma ↗
May saw a drug ad spending slump across the majority of the top ten drug ad spenders with AbbVie's Skyrizi and…
The WeekFierceBiotech ↗
Parabilis Medicines' IPO has lived up to the hype-securing $670 million for the largest listing in the biotech…
The WeekBriefing
EY’s 36th Biotech Beyond Borders report forecasts 12% industry revenue growth in 2026 amid heavy deal flow and…
The WeekDrug Channels ↗
This week, we're rerunning some popular posts while we prepare for Friday's live video webinar: 340B in 2026: …
The WeekDrug Channels ↗
This week, we're rerunning some popular posts while we prepare for Friday's live video webinar: 340B in 2026: …
The WeekSTAT News ↗
"I know what I'm getting into": Dawn Zuidgeest-Craft on starting medical residency at almost 73.…
The WeekAJMC ↗
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale…
The WeekBioPharma Dive ↗
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-w…
The WeekPharmaVoice ↗
Rivus Pharmaceuticals' CEO Jorge Bartolome said the biotech is on track to build a "truly differentiated" card…
The WeekPharmaVoice ↗
With COVID's windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly b…
The WeekFiercePharma ↗
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts' notes and IQVIA data to monitor…
The WeekFierceBiotech ↗
Bial has stopped development in a subpopulation of Parkinson's disease patients after its phase 2b trial misse…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.